Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net – Burnie Online News
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Continue Reading
-
General13 hours agoMatildas vs Panama international friendly — live blog and scores from Bunbury
-
Noosa News16 hours agoSearch for man who ‘faked death’ slowed by unusual French law
-
General14 hours agoTariff letters to 12 countries going out Monday: Trump
-
General20 hours agoBeware of dog injuries from jackets and jumpers rubbing on skin in cold weather